Huntington National Bank Increases Holdings in Boston Scientific Co. (NYSE:BSX)

Huntington National Bank lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 7.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,198,556 shares of the medical equipment provider's stock after buying an additional 84,830 shares during the quarter. Huntington National Bank owned about 0.08% of Boston Scientific worth $100,439,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of BSX. Eagle Bay Advisors LLC grew its position in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 309 shares in the last quarter. First Foundation Advisors purchased a new position in Boston Scientific during the 1st quarter valued at about $25,000. Triad Wealth Partners LLC bought a new stake in shares of Boston Scientific during the second quarter valued at about $26,000. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific in the third quarter worth about $28,000. Finally, Andra AP fonden bought a new position in shares of Boston Scientific in the second quarter valued at approximately $29,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BSX shares. Bank of America upped their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. BTIG Research increased their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Robert W. Baird boosted their target price on Boston Scientific from $90.00 to $91.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. Mizuho raised their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Finally, StockNews.com lowered Boston Scientific from a "buy" rating to a "hold" rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Trading Down 0.5 %

BSX stock traded down $0.41 during trading on Thursday, hitting $88.36. 1,649,549 shares of the company traded hands, compared to its average volume of 6,048,828. The company has a 50-day moving average of $85.03 and a 200-day moving average of $79.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 1 year low of $53.56 and a 1 year high of $89.30. The firm has a market capitalization of $130.23 billion, a PE ratio of 73.36, a P/E/G ratio of 2.61 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same quarter last year, the business earned $0.50 earnings per share. The business's revenue was up 19.3% on a year-over-year basis. Analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares of the company's stock, valued at approximately $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 309,270 shares of company stock valued at $26,196,718. Insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.